You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recombinant human thrombopoietin injection

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Disease Chronic, Thrombocytopenia Trial in Beijing (recombinant human thrombopoietin injection)

Not yet recruiting
  • Liver Disease Chronic
  • Thrombocytopenia
  • recombinant human thrombopoietin injection
  • Beijing, Beijing, China
    Peking University First Hospital
Dec 31, 2021

Chemo-induced Thrombocytopenia Trial in Shanghai (QL0911)

Completed
  • Chemotherapy-induced Thrombocytopenia
  • Shanghai, Shanghai, China
    Shanghai East Hospital
May 5, 2023

Chemo-induced Thrombocytopenia Trial in Shanghai (QL0911, Placebo)

Recruiting
  • Chemotherapy-induced Thrombocytopenia
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Sep 21, 2022

Sepsis, Thrombocytopenia Trial in Shanghai (rhTPO, Placebo)

Recruiting
  • Sepsis
  • Thrombocytopenia
  • Shanghai, Shanghai, China
    Shanghai General Hospital, Shanghai Jiaotong University
Oct 25, 2022

Immune Thrombocytopenia, Pregnancy Related Trial (intravenous immunoglobulin plus low dose recombinant human thrombopoietin

Not yet recruiting
  • Immune Thrombocytopenia
  • Pregnancy Related
  • intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)
  • intravenous immunoglobulin
  • (no location specified)
Dec 1, 2022

Pneumonia, Thrombocytopenia Trial (recombinant human thrombopoietin, normal saline)

Not yet recruiting
  • Pneumonia
  • Thrombocytopenia
  • recombinant human thrombopoietin
  • normal saline
  • (no location specified)
Jan 19, 2022

Immune Thrombocytopenia Trial in Beijing (Prednisone, Recombinant Human TPO)

Recruiting
  • Immune Thrombocytopenia
  • Beijing, China
    Peking University Insititute of Hematology, Peking University Pe
Apr 17, 2022

Malignant Melanomas Trial in Fuzhou (Recombinant Human Adenovirus Type 5 Injection)

Enrolling by invitation
  • Malignant Melanomas
  • Recombinant Human Adenovirus Type 5 Injection
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital, Department of Internal Medicine, Ward 19
Jul 7, 2023

Low/Intermediate Risk-1 MDS Trial in Beijing (Danazol + rhTPO (recombinant human thrombopoietin injection), Danazol + sodium

Active, not recruiting
  • Low/Intermediate Risk-1 MDS
  • Danazol + rhTPO (recombinant human thrombopoietin injection)
  • Danazol + sodium chloride
  • Beijing, China
    Peking union medical college hospital
Mar 26, 2020

Advanced Solid Tumors Trial in Hangzhou, Shanghai (Recombinant human IL-21 oncolytic vaccinia virus injection)

Not yet recruiting
  • Advanced Solid Tumors
  • Recombinant human IL-21 oncolytic vaccinia virus injection
  • Hangzhou, Zhejiang, China
  • +1 more
Jun 21, 2023

Poor Graft Function Trial (decitabine, umbilical cord blood, Granulocyte-colony stimulating factor)

Not yet recruiting
  • Poor Graft Function
  • (no location specified)
Dec 29, 2022

Malignant Melanoma, Liver Metastases Trial (Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel)

Not yet recruiting
  • Malignant Melanoma
  • Liver Metastases
  • Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
  • (no location specified)
Dec 23, 2022

Primary Hepatocellular Carcinoma, Portal Vein Thrombosis Trial (Recombinant human adenovirus type 5 + TACE)

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • Recombinant human adenovirus type 5 + TACE
  • (no location specified)
May 14, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Severe Hemophilia A Trial in China (FRSW117)

Not yet recruiting
  • Severe Hemophilia A
  • Beijing, China
  • +27 more
Nov 16, 2023

Acute Gout Trial in Nanchang (rhTNFR-Fc, Triamcinolone Acetonide)

Not yet recruiting
  • Acute Gout
  • Nanchang, Jiangxi, China
    Department of Rheumatology and Clinical Immunology, Jiangxi Prov
Jun 28, 2023

PEGylated GH for Treatment of Short Stature in Chinese

Recruiting
  • Growth Hormone Treatment
  • Growth Disorders
  • Polyethylene glycol recombinant human growth hormone injection
  • Beijing, Beijing, China
    Department of Endocrinology, Genetics, Metabolism
Sep 12, 2023

Metastatic Gastric Cancer Trial in Beijing (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), Nivolumab

Recruiting
  • Metastatic Gastric Cancer
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • Nivolumab Injection
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Aug 23, 2023

Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

Not yet recruiting
  • Poor Graft Function
  • (no location specified)
Jun 8, 2023

Lymphoma Trial in Changchun (PEG-rhG-CSF, RhG-CSF)

Not yet recruiting
  • Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 18, 2023

Locally Advanced/Metastatic Solid Tumors Trial (PE0116&PE0105)

Not yet recruiting
  • Locally Advanced/Metastatic Solid Tumors
  • (no location specified)
Mar 24, 2023

Hemophilia A, Hemophilia B Trial in China (Recombinant human activated coagulation factor VII for injection)

Recruiting
  • Hemophilia A
  • Hemophilia B
  • Recombinant human activated coagulation factor VII for injection
  • Chongqing, Chongqing, China
  • +8 more
Aug 2, 2022

Severe Hemophilia A Trial in China (ADVATE, FRSW117)

Completed
  • Severe Hemophilia A
  • Guangzhou, Guangzhou, China
  • +3 more
Jun 27, 2022

Hemophilia A Trial in China (ADVATE, FRSW107)

Recruiting
  • Hemophilia A
  • Beijing, Beijing, China
  • +5 more
Jun 27, 2022

Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • camrelizumab for Injection
  • (no location specified)
Nov 13, 2023